Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Fluorouracil 12Oxaliplatin 11Leucovorin 10Irinotecan 7Capecitabine 7regorafenib 4Radiotherapy 4Bevacizumab 4aflibercept 2Reverse Transcriptase Polymerase Chain Reaction 2Radiation 2Neoadjuvant Therapy 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1pembrolizumab 1lonafarnib 1irofulven 1infigratinib 1dehydroftorafur 1balstilimab 1XELOX 1Trifluridine 1Trastuzumab 1Transplantation 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Rectal Neoplasms × dehydroftorafur × Clear all
NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡